Skip to main content
VRXASector not reported

Veraxa Biotech AG - Post de-SPAC (VRXA) Insider Trading

In the last 90 days, 4 Veraxa Biotech AG - Post de-SPAC (VRXA) insiders reported 4 open-market purchases totaling $125,410 and no sales. The most recent open-market purchase was reported on Oct 20, 2026. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
1
90-day purchase value
$125,410
Corporate buyers
4
Latest transaction
Oct 20, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Oct 20, 2026Christoph Samuel ZieglerCorporate insiderOpen Market Purchase30,000$1.09$32,700
Sep 10, 2026Warren HosseinionCorporate insiderOpen Market Purchase6,024$1.67$10,060
Aug 27, 2026Oliver Rolf BaumannCorporate insiderOpen Market Purchase50,000$1.50$75,000
Aug 27, 2026Christoph Rudiger AntzChief Executive OfficerOpen Market Purchase5,000$1.53$7,650

Common questions

VRXA insider trading FAQ

Are VRXA insiders buying or selling?
Over the last 90 days, VRXA insiders were net buyers, reporting $125,410 of open-market purchases and $0.00 of sales.
When was the last VRXA insider purchase?
The most recent open-market purchase of Veraxa Biotech AG - Post de-SPAC stock by an insider was reported on Oct 20, 2026, one of 4 purchases in the last 90 days.
Where does VRXA insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that Veraxa Biotech AG - Post de-SPAC officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.